Revolution Medicines (NASDAQ:RVMD) Posts Earnings Results, Beats Estimates By $0.45 EPS

Key Points

• Revolution Medicines beat quarterly estimates: It reported a loss of $1.90 per share, $0.45 better than consensus, and revenue of $197.56 million versus analysts’ $25.58 million estimate.
• RASONQUE generated about $197.6 million in U.S. product revenue during roughly five weeks on the market, with more than 5,000 patients treated. Management cautioned that early demand included temporary factors, so it may not reflect the product’s normalized launch trajectory.
• R&D and SG&A expenses climbed to $417.1 million and $153.3 million, contributing to a $407.5 million quarterly net loss. The company maintained 2026 GAAP operating-expense guidance of $2.1 billion–$2.2 billion.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($1.90) EPS for the quarter, beating the consensus estimate of ($2.35) by $0.45, FiscalAI reports. The business had revenue of $197.56 million for the quarter, compared to analysts' expectations of $25.58 million.

Here are the key takeaways from Revolution Medicines' conference call:

• RASONQUE generated $197.6 million in net product revenue during roughly five weeks of U.S. commercialization, with more than 5,000 patients treated commercially and prescribing across academic and community settings. Management cautioned that early demand included finite expanded-access transitions and patients awaiting approval, so the initial results do not yet indicate the launch’s normalized trajectory.
• RASONQUE received a positive opinion from the European Medicines Agency’s CHMP, with a European Commission decision still pending, and NCCN added it as a preferred subsequent-therapy option in pancreatic cancer; the guideline also addresses settings beyond the FDA-approved indication. The company said more than 90% of U.S. pancreatic-cancer covered lives were represented by plans with reimbursed claims, although formal payer policies are still developing.
• Revolution advanced its pivotal pipeline: U.S. enrollment is complete in the first-line pancreatic cancer RASolute 303 study, global enrollment is expected to finish in the first half of 2027, and the RASONQUE–zoldonrasib doublet trial began dosing. It also initiated first-line lung cancer studies and is starting a global Phase III colorectal cancer trial, with BeOne funding and conducting that study.
• R&D and SG&A expenses rose to $417.1 million and $153.3 million, respectively, contributing to a quarterly net loss of $407.5 million. The company reiterated 2026 GAAP operating-expense guidance of $2.1 billion–$2.2 billion and expects expenses to increase in 2027 as it expands development and commercialization spending.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock traded up $5.47 on Wednesday, reaching $199.70. 2,528,849 shares of the stock were exchanged, compared to its average volume of 2,784,084. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines has a twelve month low of $58.00 and a twelve month high of $224.31. The firm has a market capitalization of $42.80 billion, a price-to-earnings ratio of -22.64 and a beta of 1.44. The business has a 50 day moving average price of $198.21 and a two-hundred day moving average price of $156.90.

Insider Buying and Selling

In other Revolution Medicines news, insider Stephen Kelsey sold 92,531 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the completion of the transaction, the insider directly owned 291,876 shares of the company's stock, valued at approximately $59,064,027.36. This trade represents a 24.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lorence Kim sold 56,000 shares of Revolution Medicines stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $203.24, for a total transaction of $11,381,440.00. Following the sale, the director owned 17,090 shares of the company's stock, valued at approximately $3,473,371.60. The trade was a 76.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 290,991 shares of company stock worth $59,422,765 in the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RVMD. Royal Bank Of Canada boosted their target price on Revolution Medicines from $259.00 to $260.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 14th. Evercore reiterated an "outperform" rating and issued a $320.00 price target on shares of Revolution Medicines in a research note on Thursday, August 27th. Brookline Capital Markets assumed coverage on Revolution Medicines in a research note on Monday, September 28th. They set a "buy" rating and a $318.00 price target on the stock. Oppenheimer upped their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an "outperform" rating in a report on Thursday, August 27th. Finally, Stifel Nicolaus increased their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $242.90.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company's research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.